Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.
Liberato
Bernardo
B
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Riethmuller
Adrienne
A
Comenzo
Raymond L
RL
Lis
Eric
E
Raizer
Jeffrey J
JJ
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008279:Magnetic Resonance Imaging; D008297:Male; D011859:Radiography; D000069283:Rituximab; D013116:Spinal Cord / Q000000981:diagnostic imaging / Q000473:pathology; D013118:Spinal Cord Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D000069283:Rituximab